Search results
The research of Shaji Kumar, M.D., focuses on development of novel drugs for treatment of myeloma. Dr. Kumar's research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma.
Shaji Kumar began his career as a cinematographer for Malayalam films, He has frequently collaborated with leading Indian filmmakers like Shaji Kailas, Joshiy, Vinayan and Vysakh, before moving on to balance those commitments alongside Tamil films.
YearTitleLanguage2024Malayalam2023Malayalam2022Malayalam2022MalayalamShaji Kumar, MD is a consultant in the Division of Hematology at Mayo Clinic, and Professor of Medicine in the College of Medicine, Mayo Clinic, Rochester, MN. He is currently the Medical Director for the Cancer Center Clinical Trials Office.
Sep 19, 2022 · (WASHINGTON, Sept. 19, 2022) — Shaji Kumar, MD, an expert in multiple myeloma and monoclonal gammopathies, has been named the next Editor-in-Chief of The Hematologist: ASH News and Reports, the official member news magazine of the American Society of Hematology (ASH).
Oct 10, 2022 · Shaji K. Kumar, MD, an expert in multiple myeloma and monoclonal gammopathies, has been appointed to the position of Editor-in-Chief of The Hematologist: ASH News and Reports, the official member news magazine of the American Society of Hematology (ASH).
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the evolving treatment paradigm for patients with newly diagnosed multiple myeloma in which clinical trials are suggesting the addition of a fourth drug to induction treatment regimens and new drug classes are improving treatment for those not eligible for transplantation.
People also ask
Who is Shaji Kumar?
Who is Juhi Kumar?
Who is Shashi Kumar?
Who is Shailaja Kumar?
Jul 22, 2021 · We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab.
